Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

Anouk K. M. Claessens , Jan J. V. Busschbach, Bram L. T. Ramaekers, Frans L. G. Erdkamp, Jeanette M. Bouma, A. Elise van Leeuwen-Stok, Vivianne C. G. Tjan-Heijnen , and Monique E. M. M. Bos; on behalf of the Dutch Breast Cancer Research Group (BOOG) Department of Medical Oncology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus Medical Centre, Rotterdam, The Netherlands; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Medical Oncology, Zuyderland Medical Centre, Geleen, The Netherlands; Department of Trial Registration, Comprehensive Cancer Centre the Netherlands, Rotterdam, The Netherlands; Dutch Breast Cancer Research Group, BOOG Study Center, Amsterdam, The Netherlands; Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands

• Publication year

  2022

• Venue

  Acta oncologica

• Publication date

  2022-02-09

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1080/0284186X.2022.2033832PMID 35139727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

  2020cited by this paper
• The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.

  2020cited by this paper
• Bevacizumab

  2019cited by this paper
• The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

  2019cited by this paper
• Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

  2018cited by this paper
• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

  2018cited by this paper
• Burden of early, advanced and metastatic breast cancer in The Netherlands

  2018cited by this paper
• A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium

  2017cited by this paper
• Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.

  2017cited by this paper
• Methods For The Economic Evaluation Of Health Care Programmes

  2016cited by this paper
• Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer

  2013cited by this paper
• Hormonal Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC HR+HER2-): Pre and Post-Progression Costs Under the Public Health Care System (SUS) and Societal Perspectives in Brazil

  2013cited by this paper
• The Costs of Treating Breast Cancer in the US

  2012cited by this paper
• A primer on cost-effectiveness analyses for vascular surgeons.

  2012cited by this paper
• Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer

  2012cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Projections of the cost of cancer care in the United States: 2010-2020.

  2011cited by this paper
• Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

  2011cited by this paper
• The costs of breast cancer prior to and following diagnosis

  2011cited by this paper
• Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

  2010cited by this paper
• Economic/societal burden of metastatic breast cancer: a US perspective.

  2010cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

  2009cited by this paper
• Economic burden associated with breast cancer recurrence

  2006cited by this paper
• Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

  2004cited by this paper
• Cost of Illness Associated with Metastatic Breast Cancer

  2004cited by this paper
• The estimation of a preference-based measure of health from the SF-36.

  2002cited by this paper

• Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review

  2024cites this paper